Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Neuropathy, Painful
Conditions
Diabetic Neuropathy, Painful
Trial Timeline
Nov 1, 2008 → Jun 1, 2010
NCT ID
NCT00785577About Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mg
Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mg is a phase 2 stage product being developed by Eli Lilly for Diabetic Neuropathy, Painful. The current trial status is completed. This product is registered under clinical trial identifier NCT00785577. Target conditions include Diabetic Neuropathy, Painful.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00785577 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetic Neuropathy, Painful